Oruka Therapeutics, Inc. Cash Flow Conversion Efficiency
Oruka Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Oruka Therapeutics, Inc. (ORKA) has a cash flow conversion efficiency ratio of -0.030x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.15 Million) by net assets ($1.11 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oruka Therapeutics, Inc. (2005–2025)
Cash flow conversion efficiency of Oruka Therapeutics, Inc. from 2005 to 2025. This chart illustrates how Oruka Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Oruka Therapeutics, Inc. share price for real-time trading data and today's change.
Oruka Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Oruka Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oruka Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oruka Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see how much is Oruka Therapeutics, Inc. worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Warehouses de Pauw Comm VA
BR:WDP
|
0.015x |
|
SFS Group AG
SW:SFSN
|
0.099x |
|
CSW Industrials Inc
NASDAQ:CSWI
|
0.025x |
|
Eagle Materials Inc
NYSE:EXP
|
0.104x |
|
Vista Oil Gas ADR
NYSE:VIST
|
0.280x |
|
Cogent Biosciences Inc
NASDAQ:COGT
|
-0.124x |
|
CNO Financial Group Inc
NYSE:CNO
|
0.060x |
|
Methanex Corporation
TO:MX
|
0.127x |
Annual Cash Flow Conversion Efficiency for Oruka Therapeutics, Inc. (2005–2025)
The table below shows the annual cash flow conversion efficiency of Oruka Therapeutics, Inc. from 2005 to 2025. Review Oruka Therapeutics, Inc. (ORKA) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $471.93 Million | $-88.21 Million | -0.187x | -23.52% |
| 2024-12-31 | $382.22 Million | $-57.84 Million | -0.151x | +42.21% |
| 2022-12-31 | $41.67 Million | $-10.91 Million | -0.262x | +28.76% |
| 2021-12-31 | $51.04 Million | $-18.76 Million | -0.368x | -121.36% |
| 2020-12-31 | $46.52 Million | $-7.72 Million | -0.166x | +73.68% |
| 2019-12-31 | $7.61 Million | $-4.80 Million | -0.631x | +53.84% |
| 2018-12-31 | $6.03 Million | $-8.24 Million | -1.367x | +19.63% |
| 2017-12-31 | $10.28 Million | $-17.47 Million | -1.700x | -151.82% |
| 2016-12-31 | $22.19 Million | $-14.99 Million | -0.675x | -144.04% |
| 2015-12-31 | $38.07 Million | $-10.53 Million | -0.277x | +56.64% |
| 2014-12-31 | $14.74 Million | $-9.41 Million | -0.638x | -88.01% |
| 2013-12-31 | $15.58 Million | $-5.29 Million | -0.339x | +75.81% |
| 2012-12-31 | $2.91 Million | $-4.08 Million | -1.403x | -15.55% |
| 2011-12-31 | $5.73 Million | $-6.96 Million | -1.214x | +1.24% |
| 2010-12-31 | $6.77 Million | $-8.32 Million | -1.229x | +78.16% |
| 2009-12-31 | $7.41 Million | $-41.73 Million | -5.630x | -262.54% |
| 2008-12-31 | $-5.31 Million | $-18.40 Million | 3.463x | +609.88% |
| 2007-12-31 | $67.66 Million | $-45.96 Million | -0.679x | -28.01% |
| 2006-12-31 | $69.84 Million | $-37.06 Million | -0.531x | +48.98% |
| 2005-12-31 | $56.76 Million | $-59.03 Million | -1.040x | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-… Read more